Skip to main content

NEW YORK (TheStreet) -- The evolution of diabetes treatment will continue to improve as the years go on. TheStreet's Jill Malandrino is with Nadav Kidron, CEO of Oramed Pharmaceuticals (ORMP) - Get Oramed Pharmaceuticals Inc. Report, to discuss the company's new treatment.

Kidron said there are three stages in which patients with Type II diabetes act to treat it: changing their diet and lifestyle, taking medicine orally, and finally, using insulin pumps or injections.

Oramed has created an ingestible insulin pill that patients would take in the second stage of their process.

By administering the drug early enough, Kidron said, the patient's need to use insulin injections or pumps would be postponed.

TheStreet Recommends

He added that oral administration is much better than injection. By performing the latter, the insulin is injected directly into the bloodstream, whereas an ingestible pill goes first to the liver, which regulates the secretion of insulin into the bloodstream.

Kidron concluded that it's an exciting time, as the company is expected to complete a Phase II trial for the drug by the end of the year, and is also working on a similar project for Type I diabetes.

-- Written by Bret Kenwell in Petoskey, Mich.

Follow @BretKenwell

Bret Kenwell currently writes, blogs and also contributes to Robert Weinstein's Weekly Options Newsletter. Focuses on short-to-intermediate-term trading opportunities that can be exposed via options. He prefers to use debit trades on momentum setups and credit trades on support/resistance setups. He also focuses on building long-term wealth by searching for consistent, quality dividend paying companies and long-term growth companies. He considers himself the surfer, not the wave, in relation to the market and himself. He has no allegiance to either the bull side or the bear side.